|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2006-12-5
|
|
pubmed:abstractText |
We evaluated whether posttreatment prostatic-specific antigen doubling time (PSADT) was predictive of prostate cancer mortality by testing the Prentice requirements for a surrogate endpoint.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1879-355X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
66
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1064-71
|
|
pubmed:dateRevised |
2008-10-7
|
|
pubmed:meshHeading |
pubmed-meshheading:16979837-Adult,
pubmed-meshheading:16979837-Aged,
pubmed-meshheading:16979837-Aged, 80 and over,
pubmed-meshheading:16979837-Humans,
pubmed-meshheading:16979837-Male,
pubmed-meshheading:16979837-Metabolic Clearance Rate,
pubmed-meshheading:16979837-Middle Aged,
pubmed-meshheading:16979837-Proportional Hazards Models,
pubmed-meshheading:16979837-Prostate-Specific Antigen,
pubmed-meshheading:16979837-Prostatic Neoplasms,
pubmed-meshheading:16979837-Radiotherapy Dosage,
pubmed-meshheading:16979837-Reproducibility of Results,
pubmed-meshheading:16979837-Risk Assessment,
pubmed-meshheading:16979837-Risk Factors,
pubmed-meshheading:16979837-Sensitivity and Specificity,
pubmed-meshheading:16979837-Survival Analysis,
pubmed-meshheading:16979837-Survival Rate,
pubmed-meshheading:16979837-Treatment Outcome,
pubmed-meshheading:16979837-United States
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
|
|
pubmed:affiliation |
Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA. Richard.Valicenti@mail.tju.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|
